ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2011
Annexin A2 promotes glioma cell invasion and tumor progression.
Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 116 citations in OpenAlex.
- Annexin A2 associated with bevacizumab resistance and infiltrative escape in glioblastoma.Journal of neuro-oncology · 2026Article
- Machine perception liquid biopsy identifies brain tumours via systemic immune and tumour microenvironment signature.Nature nanotechnology · 2026Article
- Annexin A2-dependent extracellular vesicle proteome modulates pre-metastatic stromal fibroblast behavior in triple-negative breast cancer.Cell communication and signaling : CCS · 2026Article
- Machine-learning assisted subclassification of glioblastoma by developing an endoplasmic reticulum stress-related methylation signature.Frontiers in oncology · 2026Article
- Multipath interaction network of annexin A2: multifaceted regulation and translational perspectives in neurological diseases.Frontiers in genetics · 2026Review
- Annexin A2: regulating glioma's fate and a potential therapeutic target.Medical oncology (Northwood, London, England) · 2025Article
- Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastoma.Journal of experimental & clinical cancer research : CR · 2025Article
- Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment.Discover oncology · 2024Review
- Glioblastoma Tumor Microenvironment: An Important Modulator for Tumoral Progression and Therapy Resistance.Current issues in molecular biology · 2024Review
- The role of annexins in central nervous system development and disease.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Silencing AHNAK promotes nasopharyngeal carcinoma progression by upregulating the ANXA2 protein.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Recombinantly expressed MeICT, a new toxin from Mesobuthus eupeus scorpion, inhibits glioma cell proliferation and downregulates Annexin A2 and FOXM1 genes.Biotechnology letters · 2022Article
- The association between Annexin A2 and epithelial cell adhesion molecule in breast cancer cells.Cancer reports (Hoboken, N.J.) · 2022Article
- Matrisome changes in Parkinson's disease.Analytical and bioanalytical chemistry · 2022Article
- A novel DNA aptamer targeting lung cancer stem cells exerts a therapeutic effect by binding and neutralizing Annexin A2.Molecular therapy. Nucleic acids · 2022Article
- ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous CystadenocarcinomaFrontiers in oncology · 2022Article
- Lucanthone Targets Lysosomes to Perturb Glioma Proliferation, Chemoresistance and Stemness, and Slows Tumor GrowthFrontiers in oncology · 2022Article
- Pathobiological functions and clinical implications of annexin dysregulation in human cancers.Frontiers in cell and developmental biology · 2022Review
- ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppression.Scientific reports · 2021Article
- TAGLN2 promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of colorectal cancer cells by activating STAT3 signaling through ANXA2.Oncology letters · 2021Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Gliomas are highly invasive, lethal brain tumors. Tumor-associated proteases play an important role in glioma progression. Annexin A2 is overexpressed in many cancers and correlates with increased plasmin activity on the tumor cell surface, which mediates degradation of extracellular matrix and promotes neoangiogenesis to facilitate tumor growth. In this study, we used two glioma cell lines, mouse GL261-EGFP and rat C6/LacZ, as well as stable clones transfected with an annexin A2 knockdown construct. We find that the annexin A2 knockdown decreased glioma cell migration in vitro and decreased membrane-bound plasmin activity. In vivo, we injected the glioma cells into the rodent brain and followed glioma progression. Knockdown of annexin A2 in glioma cells decreased tumor size and slowed tumor progression, as evidenced by decreased invasion, angiogenesis, and proliferation, as well as increased apoptosis in the tumor tissue of the annexin A2 knockdown group. Moreover, we report that the levels of expression of annexin A2 in human glioma samples correlate with their degree of malignancy. Together, our findings demonstrate that inhibition of annexin A2 expression in glioma cells could become a new target for glioma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.